Intravitreal aflibercept injection in patients with myopic choroidal neovascularization: The MYRROR study

Ophthalmology

Volumn 122, Issue 6, 2015, Pages 1220-1227

  Ikuno, Yasushi ^a   Ohno Matsui, Kyoko ^b   Wong, Tien Yin ^c   Korobelnik, Jean Francois ^d,e,f   Vitti, Robert ^g   Li, Tummy ^h   Stemper, Brigitte ^i,j   Asmus, Friedrich ^i,k   Zeitz, Oliver ^i,l   Ishibashi, Tatsuro ^m  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d HÔPITAL PELLEGRIN   (France)

^e UNIVERSITÉ DE BORDEAUX   (France)

^f INSERM   (France)

^g REGENERON PHARMACEUTICALS INC   (United States)

^h Bayer Pharma AG   (China)

ⁱ BAYER PHARMA AG   (Germany)

^j UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^k UNIVERSITY OF TÜBINGEN   (Germany)

^l UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^m KYUSHU UNIVERSITY   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; ANGIOGENESIS INHIBITOR; HYBRID PROTEIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VEGFA PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BEST CORRECTED VISUAL ACUITY; CATARACT; CENTRAL RETINAL THICKNESS; CONJUNCTIVAL HEMORRHAGE; CONTROLLED STUDY; DISEASE DURATION; DIZZINESS; DRUG SAFETY; DRY EYE; FEMALE; HEADACHE; HIGH MYOPIA; HUMAN; INTRAOCULAR HEMORRHAGE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYOPIC CHOROIDAL NEOVASCULARIZATION; NATIONAL EYE INSTITUTE VISUAL FUNCTION QUESTIONNAIRE; NAUSEA; OPTICAL COHERENCE TOMOGRAPHY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PUNCTATE KERATITIS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY; ANTAGONISTS AND INHIBITORS; CHOROIDAL NEOVASCULARIZATION; CLINICAL TRIAL; COMPLICATION; DOUBLE BLIND PROCEDURE; INTRAVITREAL DRUG ADMINISTRATION; MIDDLE AGED; MYOPIA, DEGENERATIVE; PATHOPHYSIOLOGY; PHYSIOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; CHOROIDAL NEOVASCULARIZATION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; MYOPIA, DEGENERATIVE; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84930039255     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2015.01.025     Document Type: Article

References (27)

1. R. Rashid, and E. Grossniklaus Update on the pathology of pathologic myopia R.F. Spaide, K. Ohno-Matsui, A. Yannuzzi, Pathologic Myopia 2014 Springer New York 187 209
2. T.Y. Wong, A. Ferreira, and R. Hughes Epidemiology and disease burden of pathologic myopia and myopic choroidal neovascularization: an evidence-based systematic review Am J Ophthalmol 157 2014 9 25
3. T. Asakuma, M. Yasuda, and T. Ninomiya Prevalence and risk factors for myopic retinopathy in a Japanese population: the Hisayama Study Ophthalmology 119 2012 1760 1765
4. A. Iwase, M. Araie, and A. Tomidokoro Prevalence and causes of low vision and blindness in a Japanese adult population: the Tajimi Study Ophthalmology 113 2006 1354 1362
5. C.A. McCarty, P.M. Livingston, and H.R. Taylor Prevalence of myopia in adults: implications for refractive surgeons J Refract Surg 13 1997 229 234
6. S. Vitale, R.D. Sperduto, and F.L. Ferris III Increased prevalence of myopia in the United States between 1971-1972 and 1999-2004 Arch Ophthalmol 127 2009 1632 1639
7. S.Y. Cohen, A. Laroche, and Y. Leguen Etiology of choroidal neovascularization in young patients Ophthalmology 103 1996 1241 1244
8. K. Ohno-Matsui, and T. Yoshida Myopic choroidal neovascularization: natural course and treatment Curr Opin Ophthalmol 15 2004 197 202
9. T. Yoshida, K. Ohno-Matsui, and K. Yasuzumi Myopic choroidal neovascularization: a 10-year follow-up Ophthalmology 110 2003 1297 1305
10. A. Pece, R. Brancato, and P. Avanza Laser photocoagulation of choroidal neovascularization in pathologic myopia: long-term results Int Ophthalmol 18 1994 339 344
11. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial-VIP report no. 1 Ophthalmology 108 2001 841 852
12. K.J. Blinder, M.S. Blumenkranz, and N.M. Bressler Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial-VIP report no. 3 Ophthalmology 110 2003 667 673
13. K. Neelam, C.M. Cheung, and K. Ohno-Matsui Choroidal neovascularization in pathological myopia Prog Retin Eye Res 31 2012 495 525
14. Y. Ikuno, Y. Nagai, and S. Matsuda Two-year visual results for older Asian women treated with photodynamic therapy or bevacizumab for myopic choroidal neovascularization Am J Ophthalmol 149 2010 140 146
15. H. Nakanishi, A. Tsujikawa, and Y. Yodoi Prognostic factors for visual outcomes 2-years after intravitreal bevacizumab for myopic choroidal neovascularization Eye (Lond) 25 2011 375 381
16. T. Wakabayashi, Y. Ikuno, and F. Gomi Intravitreal bevacizumab vs sub-tenon triamcinolone acetonide for choroidal neovascularization attributable to pathologic myopia Am J Ophthalmol 148 2009 591 596
17. A. Tufail, N. Narendran, and P.J. Patel Ranibizumab in myopic choroidal neovascularization: the 12-month results from the REPAIR study Ophthalmology 120 2013 1944 1945
18. A. Tufail, P.J. Patel, and S. Sivaprasad Ranibizumab for the treatment of choroidal neovascularisation secondary to pathological myopia: interim analysis of the REPAIR study Eye (Lond) 27 2013 709 715
19. S. Wolf, V.J. Balciuniene, and G. Laganovska RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia Ophthalmology 121 2014 682 692
20. U. Schmidt-Erfurth, P.K. Kaiser, and J.F. Korobelnik Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies Ophthalmology 121 2013 193 201
21. D.M. Brown, J.S. Heier, and W.L. Clark Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study Am J Ophthalmol 155 2013 429 437
22. J.F. Korobelnik, F.G. Holz, and J. Roider Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one-year results of the phase 3 GALILEO Study Ophthalmology 121 2013 202 208
23. D.V. Do, Q.D. Nguyen, and D. Boyer One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema Ophthalmology 119 2012 1658 1665
24. D. Boyer, J. Heier, and D.M. Brown Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study Ophthalmology 119 2012 1024 1032
25. J.S. Heier, D.M. Brown, and V. Chong Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration Ophthalmology 119 2012 2537 2548
26. F.G. Holz, J. Roider, and Y. Ogura VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study Br J Ophthalmol 97 2013 278 284
27. J.F. Korobelnik, D.V. Do, and U. Schmidt-Erfurth Intravitreal aflibercept for diabetic macular edema Ophthalmology 121 2014 2247 2254